Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma

Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 T-lymphocyte counts

Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy

Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus

Immunotherapy of Hepatocellular Carcinoma

PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy

Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer

Anti-cancer vaccine therapy for hematologic malignancies: An evolving era

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade